Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. (4r,5r)-5-(4-((4-(4-aza-1-azoniabicyclo(2.2.2)octan-1-ylmethyl)phenyl)methoxy)phenyl)-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-16-benzothiepin-4-ol
2. Livmarli
3. Maralixibat
1. Lopixibat Chloride
2. 228113-66-4
3. Lum-001
4. Maralixibat Chloride [usan]
5. Lum001
6. Maralixibat (chloride)
7. V78m04f0xc
8. 228113-66-4 (chloride)
9. Livmarli
10. Lum 001
11. 4-aza-1-azoniabicyclo(2.2.2)octane, 1-((4-((4-((4r,5r)-3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)methyl)phenyl)methyl)-, Chloride (1:1)
12. Chembl17879
13. (4r,5r)-5-[4-[[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1lambda6-benzothiepin-4-ol;chloride
14. 1-(4-((4-((4r,5r)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b]thiepin-5-yl)phenoxy)methyl)benzyl)-1,4-diazabicyclo[2.2.2]octan-1-ium Chloride
15. Lopixibat Chloride [inn]
16. Unii-v78m04f0xc
17. Shp 625
18. Schembl6336189
19. Shp625
20. Maralixibat Chloride (usan/inn)
21. Dtxsid701337104
22. Maralixibat Chloride [inn]
23. Maralixibat Chloride [who-dd]
24. Hy-16747
25. Maralixibat Chloride [orange Book]
26. Cs-0012347
27. D10952
28. Q27291628
Molecular Weight | 710.4 g/mol |
---|---|
Molecular Formula | C40H56ClN3O4S |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 13 |
Exact Mass | 709.3680061 g/mol |
Monoisotopic Mass | 709.3680061 g/mol |
Topological Polar Surface Area | 78.5 Ų |
Heavy Atom Count | 49 |
Formal Charge | 0 |
Complexity | 1080 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Treatment of Progressive Familial Intrahepatic Cholestasis
Treatment of Alagille syndrome
Treatment of biliary atresia
A - Alimentary tract and metabolism
A05 - Bile and liver therapy
A05A - Bile therapy
A05AX - Other drugs for bile therapy
A05AX04 - Maralixibat chloride
Details:
Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor and NMPA has accepted the New Drug Application for the treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis.
Lead Product(s): Maralixibat Chloride
Therapeutic Area: Genetic Disease Brand Name: Livmarli
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Lead Product(s) : Maralixibat Chloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor and NMPA has accepted the New Drug Application for the treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholest...
Brand Name : Livmarli
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 16, 2023
Details:
Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor and received Marketing Approval for the treatment of Cholestatic Pruritus in Patients with Alagille Syndrome.
Lead Product(s): Maralixibat Chloride
Therapeutic Area: Genetic Disease Brand Name: Livmarli
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Lead Product(s) : Maralixibat Chloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CANbridge Announces Marketing Approval of CAN108 (邁芮倍®/LIVMARLI®) in Taiwan for the Treatm...
Details : Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor and received Marketing Approval for the treatment of Cholestatic Pruritus in Patients with Alagille Syndrome.
Brand Name : Livmarli
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 09, 2023
Details:
Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor and received Marketing Approval for the treatment of Cholestatic Pruritus in Patients with Alagille Syndrome.
Lead Product(s): Maralixibat Chloride
Therapeutic Area: Genetic Disease Brand Name: Livmarli
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2023
Lead Product(s) : Maralixibat Chloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Chol...
Details : Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor and received Marketing Approval for the treatment of Cholestatic Pruritus in Patients with Alagille Syndrome.
Brand Name : Livmarli
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 08, 2023
Details:
Livmarli® (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor and received Marketing Approval for the treatment of Cholestatic Pruritus in Patients with Alagille Syndrome.
Lead Product(s): Maralixibat Chloride
Therapeutic Area: Genetic Disease Brand Name: Livmarli
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2023
Lead Product(s) : Maralixibat Chloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CANbridge Announces Marketing Approval of CAN108 (LIVMARLI®) in China for the Treatment of Choles...
Details : Livmarli® (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor and received Marketing Approval for the treatment of Cholestatic Pruritus in Patients with Alagille Syndrome.
Brand Name : Livmarli
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 02, 2023
Details:
LIVMARLI® (maralixibat) oral solution is a minimally absorbed ileal bile acid transporter (IBAT) inhibitor and has also completed enrollment across the other global locations where the trial is open.
Lead Product(s): Maralixibat Chloride
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Livmarli
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Lead Product(s) : Maralixibat Chloride
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CANbridge Announces Full Enrollment Reached in China Region of the Global LIVMARLI® (CAN108) EMBA...
Details : LIVMARLI® (maralixibat) oral solution is a minimally absorbed ileal bile acid transporter (IBAT) inhibitor and has also completed enrollment across the other global locations where the trial is open.
Brand Name : Livmarli
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 30, 2023
Regulatory Info : RX
Registration Country : USA
Brand Name : LIVMARLI
Dosage Form : SOLUTION;ORAL
Dosage Strength : EQ 9.5MG BASE/ML
Packaging :
Approval Date : 2021-09-29
Application Number : 214662
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : LIVMARLI
Dosage Form : SOLUTION;ORAL
Dosage Strength : EQ 19MG BASE/ML
Packaging :
Approval Date : 2024-07-24
Application Number : 214662
Regulatory Info : RX
Registration Country : USA
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?